A3 adenosine receptor agonists

Details A3 adenosine receptor agonists A3 adenosine receptor agonists

1994-07-13

1998-06-30

Wilson, James O.

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Carbohydrate doai

514 46, 536 2722, 536 276, 536 2763, A61K 3170

Patent

active

057734232

ABSTRACT:
The present invention provides N.sup.6 -benzyladenosine-5'-N-uronamide and related substituted compounds, particularly those containing substituents on the benzyl and/or uronamide groups, and modified xanthine ribosides, as well as pharmaceutical compositions containing such compounds. The present invention also provides a method of selectively activating an A.sub.3 adenosine receptor in a mammal, which method comprises acutely or chronically administering to a mammal in need of selective activation of its A.sub.3 adenosine receptor a therapeutically effective amount of a compound which binds with the A.sub.3 receptor so as to stimulate an A.sub.3 receptor-dependent response.

REFERENCES:
patent: 3551409 (1970-12-01), Kampe et al.
patent: 5140015 (1992-08-01), Olsson et al.
patent: 5310731 (1994-05-01), Olsson et al.
patent: 5443836 (1995-08-01), Downey et al.
Journal of Medicinal Chemistry, vol, 35, No. 22, pp. 4143-4149, (1992).
Molecular Pharmacology, vol. 29, pp. 331-346 (1986).
Fozard et al., Br. J. Pharmacol., 109, 3-5 (1993).
Jacobson et al., J. Med. Chem., 35, 407-422 (1992).
Kampe et al., Chem. Abstr., 70, 88212z (1969).
Koch et al., Chem. Abstr., 72, 21921c (1970).
Kusachi et al., J. Med. Chem., 29, 989-996 (1986).
Mosselhi, Nucleos. Nucleot., 12, 431-439 (1993).
van Galen et al., Nucleos. Nucleot., 10, 1191-1193 (1991).
Ali et al., J. Biol. Chem., 265, 745-753 (1990).
Beaven et al., Trends Pharm. Sci., 15, 13-14 (1994).
Borea et al., Int. J. Purine and Pyrimidine Res., 3, 65 (1992).
Borea et al., Eur. J. Pharmacol. (Mol. Pharm. Section), 267, 55-61.
Brackett et al., Biochem. Pharmacol., 47, 801-814 (1994).
Fozard et al., Br. J. Pharmacol., 109, 3-5 (1993).
Gallo-Rodriguez et al., J. Med. Chem., 37, 636-646 (1994).
Hide et al., Mol. Pharmacol., 41, 352-359 (1992).
Jacobson et al., FEBS Letters, 323, 141-144 (1993).
Jacobson et al., FEBS Letters, 336, 57-60 (1993).
Jarvis et al., J. Pharmacol. Exp. Therap., 251, 888-893 (1989).
Jasper et al., Biochem. Pharmacol., 43, 119-130 (1992).
Linden et al., Mol. Pharmacol., 44, 524-532 (1993).
Olah et al., Mol. Pharmacol., 45, 978-982 (1994).
Salvatore et al., Proc. Natl. Acad. Sci. U.S.A., 90, 10365-10369 (1993).
Schwabe et al., Naunyn-Schmiedeberg's Arch. Pharmacol., 313, 179-187 (1980).
van Galen et al., Mol. Pharmacol., 45, 1101-1111 (1994).
van der Wenden et al., Drug Devel. Res., 31, 314 (Abstract 1190) (1994).
von Lubitz et al., Drug Devel. Res., 31, 332 (Abstract 1224) (1994).
von Lubitz et al., Neurosci. Abstr., (1994).

Affiliated with

Also associated with

Rating

A3 adenosine receptor agonists does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with A3 adenosine receptor agonists, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and A3 adenosine receptor agonists will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-1859384